Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.
Penzel N, Polosecki P, Addington J, Arango C, Asgari-Targhi A, Billah T, Bouix S, Calkins ME, Campbell DE, Cannon TD, Castro E, Cho KIK, Coleman MJ, Corcoran CM, Dwyer D, Frangou S, Fusar-Poli P, Glynn RJ, Haidar A, Harms MP, Jacobs GR, Kambeitz J, Kapur T, Kelly SM, Koutsouleris N, Abhinandan KR, Kucukemiroglu S, Kwon JS, Lewandowski KE, Li QS, Mantua V, Mathalon DH, Mittal VA, Nicholas S, Pandina GJ, Perkins DO, Potter A, Reichenberg A, Reinen J, Sand MS, Seitz-Holland J, Shah JL, Srinivasan V, Srivastava A, Stone WS, Torous J, Vangel MG, Wang J, Wolff P, Yao B, Anticevic A, Wolf DH, Zhu H, Bearden CE, McGorry PD, Nelson B, Kane JM, Woods SW, Kahn RS, Shenton ME; Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ); Cecchi G, Pasternak O.
Penzel N, et al. Among authors: polosecki p.
Schizophrenia (Heidelb). 2025 Apr 3;11(1):53. doi: 10.1038/s41537-025-00561-w.
Schizophrenia (Heidelb). 2025.
PMID: 40180950
Free PMC article.